Workflow
生物制品
icon
Search documents
嘉必优生物技术(武汉)股份有限公司 关于注销部分募集资金专项账户的公告
Sou Hu Cai Jing· 2025-09-04 18:11
Fundraising Overview - The company has successfully completed an initial public offering (IPO) of 30,000,000 shares at a price of RMB 23.90 per share, raising a total of RMB 717 million, with a net amount of RMB 648.33 million after deducting issuance costs [1][2] Fund Management and Usage - The company has established a management system for the use and management of the raised funds, ensuring compliance with regulations and protecting investor rights [2] - A tripartite supervision agreement has been signed with the underwriter and the banks to ensure that the funds are used specifically for their intended purposes [2] Account Closure - The company has closed a special account for the raised funds at China Merchants Bank, as the funds in that account have been fully utilized according to regulations [3]
华恒生物: 对外担保管理制度(2025年9月修订)
Zheng Quan Zhi Xing· 2025-09-04 16:18
Core Points - The document outlines the external guarantee management system of Anhui Huaheng Biotechnology Co., Ltd, aiming to standardize external guarantee behavior, control risks, and ensure asset safety [1][2] - The system applies to the company and its subsidiaries, defining external guarantees as the guarantees provided by the company for others, including those for its subsidiaries [1][2] - The company emphasizes the need for legal, prudent, mutual benefit, and safety principles in external guarantees, with strict risk control measures [2][3] Group 1 - External guarantees must be managed uniformly by the company, and subsidiaries cannot provide guarantees without approval [2][3] - Guarantees require the counterpart to provide counter-guarantees, which must be from parties with actual capacity to bear responsibility [2][3] - Any guarantee actions must be approved by the shareholders' meeting or the board of directors [2][3] Group 2 - The company does not proactively provide guarantees; requests must come from the guaranteed enterprises, which should have good operational status and repayment ability [10][11] - The company must analyze the credit status and risks of the guaranteed party before deciding on the guarantee [10][11] - Required documentation for guarantee applications includes basic enterprise information, financial reports, and repayment plans [10][11] Group 3 - The board of directors must thoroughly investigate the operational and credit status of the guaranteed party before approving guarantees [10][11] - The highest decision-making body for external guarantees is the shareholders' meeting, with specific thresholds for approval based on net assets and total assets [10][11] - The shareholders' meeting must approve guarantees exceeding certain limits, such as 10% of the latest audited net assets [10][11] Group 4 - Guarantee contracts must be written and include essential details such as the type and amount of the principal debt [10][11] - The company must manage guarantee contracts and related documents properly, ensuring their completeness and accuracy [10][11] - If a guaranteed party fails to fulfill repayment obligations, the company must prepare to initiate counter-guarantee recovery procedures [10][11] Group 5 - The company is responsible for disclosing external guarantee matters in accordance with regulations after board or shareholder approval [10][11] - Any department or individual involved in external guarantees must report to the board secretary and provide necessary documentation for disclosure [10][11] - Individuals responsible for guarantee matters must adhere to procedures and may face liability for violations [10][11]
华恒生物: 兴业证券股份有限公司关于安徽华恒生物科技股份有限公司部分募集资金投资项目延期的核查意见
Zheng Quan Zhi Xing· 2025-09-04 16:18
Core Viewpoint - The company has decided to postpone the completion date of the "Apple Acid Co-production Tryptophan Project" from 2025 to October 2026 due to actual construction progress and investment considerations [5][6][7]. Fundraising and Investment Project Overview - The company has successfully raised a net amount of RMB 683.81 million after deducting issuance costs of RMB 16.19 million, with all funds received by October 21, 2024 [1][2]. - The adjusted fundraising allocation for investment projects totals RMB 683.81 million, down from an initial plan of RMB 700 million [2][3]. Fund Usage and Project Status - As of June 30, 2025, the company has fully utilized the raised funds for the "Apple Acid Co-production Tryptophan Project" and the "Succinic Acid Co-production Valine/Inositol Project," with investment ratios exceeding 100% for both projects [5][6]. - The company has established a special account for the management of raised funds, ensuring compliance with regulatory requirements [2][3]. Delay Details - The postponement of the "Apple Acid Co-production Tryptophan Project" is based on market demand and technical upgrades to production equipment, with no changes to the project's investment direction or implementation [6][7]. - The company has confirmed that the delay will not adversely affect the normal operation of the company or the interests of shareholders, particularly minority investors [8]. Approval and Oversight - The decision to postpone the project has been approved by the company's board and supervisory committee, adhering to necessary regulatory procedures [8][9]. - The sponsor institution has conducted a thorough review and supports the decision, confirming that it aligns with relevant laws and regulations [8][9].
安徽华恒生物出台股份回购管理制度 规范回购行为保护投资者权益
Xin Lang Cai Jing· 2025-09-04 13:48
安徽华恒生物科技股份有限公司于2025年9月发布《股份回购管理制度》,旨在依据《公司法》《证券 法》等相关法律法规及规范性文件,结合公司章程,规范公司股份回购行为,保护投资者合法权益。 适用情形明确 决策程序严格 登录新浪财经APP 搜索【信披】查看更多考评等级 实施程序与信息披露详尽 回购股份可依公司章程规定或股东会授权,经三分之二以上董事出席的董事会会议决议。回购提议人应 明确具体提议内容,公司收到提议后应尽快召开董事会审议并公告。 公司需制定回购股份方案,经董事会或股东会决议通过后及时披露相关材料。回购期间,公司应按规定 时间发布回购进展公告,方案披露后非因充分正当事由不得变更或终止。回购期限届满或方案实施完 毕,公司应停止回购并公告结果。 此外,制度对回购股份的处理、内幕信息管理等方面也作出详细规定,确保公司股份回购行为合法合 规、公开透明,切实保护投资者权益。 声明:市场有风险,投资需谨慎。 本文为AI大模型基于第三方数据库自动发布,任何在本文出现的信 息(包括但不限于个股、评论、预测、图表、指标、理论、任何形式的表述等)均只作为参考,不构成 个人投资建议。受限于第三方数据库质量等问题,我们无法对数 ...
赛伦生物:关于参加2025年半年度科创板生物制品及CXO行业集体业绩说明会的公告
Zheng Quan Ri Bao· 2025-09-04 13:36
Group 1 - The company, Sairen Bio, announced its plan to participate in the 2025 semi-annual performance briefing for the biopharmaceutical and CXO industry on September 15, 2025 [2]
上海莱士: 关于公司部分董事及全体高级管理人员增持股份计划的公告
Zheng Quan Zhi Xing· 2025-09-04 11:14
Core Viewpoint - The management team of Shanghai Laishi Blood Products Co., Ltd. plans to increase their shareholding in the company, demonstrating confidence in the company's strategic development and long-term investment value, with a total planned investment of no less than RMB 6 million within six months [2][3]. Group 1: Shareholding Increase Plan - The increase in shareholding will be executed through centralized bidding, funded by self-raised capital [2][3]. - The management team members involved in the shareholding increase include Jun Xu, Shen Jihui, Lu Hui, Liu Zheng, Song Zhengmin, Chen Leqi, and Huang Qinbing, with their current shareholdings detailed in a table [2][3]. - The total number of shares held by the management team members, excluding those from the first employee stock ownership plan, is specified [2][3]. Group 2: Employee Stock Ownership Plan - As of the announcement date, the management team members hold remaining shares corresponding to the first employee stock ownership plan, which will only be realized upon meeting specific unlocking conditions [3]. - The management team has previously sold shares obtained from the first employee stock ownership plan after the lock-up period [3]. Group 3: Implementation Conditions - The shareholding increase plan will be executed based on a reasonable assessment of the company's stock value, and the implementation may be postponed if the stock is suspended or if market conditions change [4]. - The management team commits to not reducing their shareholdings during the implementation period and will adhere to relevant laws and regulations [4].
康希诺跌4.93% 2020年上市募52亿中信证券保荐
Zhong Guo Jing Ji Wang· 2025-09-04 09:18
Core Viewpoint - 康希诺's stock closed at 79.70 yuan, experiencing a decline of 4.93%, indicating it is currently in a state of underperformance since its IPO [1] Group 1: IPO Details - 康希诺 was listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on August 13, 2020, with an issuance of 24.8 million shares at a price of 209.71 yuan per share [1] - The total funds raised by 康希诺 amounted to 5.201 billion yuan, with a net amount of 4.979 billion yuan after deducting issuance costs, which was 3.979 billion yuan more than the original plan [1] - The company initially aimed to raise 1 billion yuan for various projects, including the construction of a second production base and vaccine development [1] Group 2: Issuance Costs - The issuance costs for 康希诺 totaled 221 million yuan, with underwriting and sponsorship fees accounting for 205 million yuan [2] - 中信证券投资有限公司 received 496,000 shares, representing 2.00% of the total shares issued, with an investment amount of 104 million yuan [2]
2025年北交所新股申购8月报:步入常态化发行期,申购收益率可观-20250904
证 券 研 究 报 告 步入常态化发行期,申购收益率可观 ——2025年北交所新股申购8月报 证券分析师:刘靖 A0230512070005 王雨晴 A0230522010003 研究支持: 吕靖华 A0230124070002 2025.09.04 主要内容 ◼ 2025年新股申购收益及收益率预测 www.swsresearch.com 证券研究报告 2 (1) 2025年8月北交所发行新股5只,募资金额12.20亿;2025年1-8月累计发行新股12只,合计募资金额37.39亿。 (2) 8月5家企业上会通过、环比+1家;5家企业终止、环比+3家;4家企业注册、环比-2家;无新增受理企业。 (3) 截止至8月末,已过会未注册企业13家,拟募资26.10亿元;已注册未发行企业3家,拟募资9.29亿元。 (1) 8月共5只直接定价新股申购。首发PEttm中值11X,环比上月-12.06%;平均顶格申购金额1160万元。 (2) 单批新股冻结资金区间为5645.43-7408.33亿元,中值7315.54亿元、环比上月+17.67%;网上中签率中值0.04%。 ◼ 融资&审核 ◼ 申购&发行 ◼ 上市&收益 ( ...
生物制品板块9月4日跌2.63%,百普赛斯领跌,主力资金净流出11.3亿元
从资金流向上来看,当日生物制品板块主力资金净流出11.3亿元,游资资金净流入2.76亿元,散户资金 净流入8.54亿元。生物制品板块个股资金流向见下表: 以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。 证券之星消息,9月4日生物制品板块较上一交易日下跌2.63%,百普赛斯领跌。当日上证指数报收于 3765.88,下跌1.25%。深证成指报收于12118.7,下跌2.83%。生物制品板块个股涨跌见下表: ...
今日看盘 | 9月4日:山西上市公司小幅下跌,24只上涨
Xin Lang Cai Jing· 2025-09-04 08:21
Market Overview - On September 4, all three major indices declined, with the Shenzhen Component Index falling by 2.83%, the Shanghai Composite Index decreasing by 1.25%, and the ChiNext Index dropping by 4.25% [1] - The Shanxi sector experienced a slight overall decline of 0.06% [1] Leading Stocks - The top-performing stock in the Shanxi sector was Dayu Biological Engineering Co., Ltd. (stock code: 871970), which rose by 3.40% [1] - Dayu Biological, established on July 23, 2014, is a high-tech enterprise based in Ruicheng, Shanxi Province, with a registered capital of 111.36 million yuan. The company focuses on the research and production of functional biological products, including feed additives and veterinary drugs, and holds 12 national invention patents [1][2] Underperforming Stocks - The worst-performing stock was Northern Copper Industry Co., Ltd. (stock code: 000737), which fell by 5.56% [1] - Northern Copper, founded in December 2002, is the largest copper producer in North China. The company underwent a significant asset restructuring in June 2020 and completed the asset transfer in November 2021, marking a major capital operation in Shanxi Province's state-owned enterprise reform [3]